Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Analysis of Drug-Related Tinnitus Based on the FDA Adverse Event Reporting System Database.
Br J Hosp Med (Lond)
December 2024
Department of Otolaryngology Head and Neck Surgery, Jinhua Hospital of Zhejiang University, Jinhua, Zhejiang, China.
Tinnitus is a very common condition, and is a side effect of many medications. The panorama of drug-induced tinnitus has widened in recent decades, and post-marketing data are needed to gain a better insight into adverse drug reactions related to tinnitus. However, there are currently few studies on drug-induced tinnitus.
View Article and Find Full Text PDFA cRGD-modified liposome for targeted delivery of artesunate to inhibit angiogenesis in endometriosis.
Biomater Sci
January 2025
Department of Gynecology, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong 510655, China.
Currently, hormonal therapy for endometriosis faces challenges in achieving a balance between treatment and preserving the chance of pregnancy. Therefore, the development of non-hormonal therapy holds significant clinical importance. Angiogenesis is a hallmark of endometriosis, and anti-angiogenic therapies targeting the hypoxia-inducible factor-1α (HIF-1α) pathway are considered potential approaches for endometriosis.
View Article and Find Full Text PDFPatients' Perceptions of the Efficacy, Safety, and Quality of the Evidence of Medicinal Cannabis: A Survey of Australian Cancer Patients.
Asia Pac J Clin Oncol
January 2025
Department of Medical Oncology, Gosford Hospital, Gosford, New South Wales, Australia.
Introduction: Despite the increased demand for medical cannabis (MC), MASCC guidelines state that there is insufficient evidence of its efficacy and safety. Although research has explored medical professionals' perceptions of MC, there is to our knowledge minimal research exploring patients' perceptions, particularly in an Australian cancer setting.
Methods: A survey of Australian cancer patients attending oncology outpatient clinics was performed.
TLR7/8/9 agonists and low-dose cisplatin synergistically promotes tertiary lymphatic structure formation and antitumor immunity.
NPJ Vaccines
January 2025
Key Laboratory of Medical Molecular Virology, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.
In situ vaccination (ISV) triggers antitumor immune responses using the patient's own cancer antigens, yet limited neoantigen release hampers its efficacy. Our novel combination therapy involves low-dose local cisplatin followed by ISV with a TLR7/8/9 agonist formulation (CR108), in which CR108 boosts and sustains the antitumor responses induced by the cisplatin-released neoantigens. In mouse models, the cisplatin+CR108 combination significantly outperformed cisplatin or CR108 alone in abrogating established 4T1 and B16 tumors.
View Article and Find Full Text PDFSudden sensorineural hearing loss (SSNHL) presents as the abrupt onset of hearing loss. Approximately 88% of SSNHL has no identifiable etiology and is termed idiopathic sudden sensorineural hearing loss (ISSHL). Hearing specialists have investigated ISSHL since the 1970s.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!